[
    [
        {
            "time": "",
            "original_text": "三年四次敲钟 药明康德这只独角兽像药神更像股神",
            "features": {
                "keywords": [
                    "药明康德",
                    "独角兽",
                    "股神"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "三年四次敲钟 药明康德这只独角兽像药神更像股神",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业周报:仿制药高毛时代过去,集中度提升将催生新巨头",
            "features": {
                "keywords": [
                    "仿制药",
                    "集中度",
                    "新巨头"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "医药生物行业周报:仿制药高毛时代过去,集中度提升将催生新巨头",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "药明康德今日在香港联交所挂牌上市",
            "features": {
                "keywords": [
                    "药明康德",
                    "香港联交所",
                    "挂牌上市"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "药明康德今日在香港联交所挂牌上市",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 10,
                "Headline_Structure": 7,
                "Source_Recency": 10
            }
        },
        {
            "time": "",
            "original_text": "「A+H」临床合同研究机构（CRO）生物医药企业泰格医药将于8月7日在联交所挂牌，这是继药明康德、康龙化成后国内第三家CRO机构，其拟募资107亿港元（13.8亿美元），为2020年截止7月30日亚洲生物医药公司IPO规模最大项目。",
            "features": {
                "keywords": [
                    "泰格医药",
                    "CRO",
                    "IPO",
                    "募资"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "「A+H」临床合同研究机构（CRO）生物医药企业泰格医药将于8月7日在联交所挂牌，这是继药明康德、康龙化成后国内第三家CRO机构，其拟募资107亿港元（13.8亿美元），为2020年截止7月30日亚洲生物医药公司IPO规模最大项目。",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "港股异动 | 药明康德（02359）首挂跌4.34% 药明生物(02269)升0.27%",
            "features": {
                "keywords": [
                    "药明康德",
                    "港股",
                    "首挂跌",
                    "药明生物",
                    "升"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "港股异动 | 药明康德（02359）首挂跌4.34% 药明生物(02269)升0.27%",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 10,
                "Headline_Structure": 9,
                "Source_Recency": 10
            }
        },
        {
            "time": "",
            "original_text": "药明康德今日杀入港股，未盈利生物医药股有点慌？",
            "features": {
                "keywords": [
                    "药明康德",
                    "港股",
                    "未盈利",
                    "生物医药"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "药明康德今日杀入港股，未盈利生物医药股有点慌？",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "药明康德H股盘初跌幅扩大至逾4%",
            "features": {
                "keywords": [
                    "药明康德",
                    "H股",
                    "盘初",
                    "跌幅"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "药明康德H股盘初跌幅扩大至逾4%",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 9,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 10,
                "Headline_Structure": 7,
                "Source_Recency": 10
            }
        },
        {
            "time": "",
            "original_text": "药明康德H股挂牌上市 构建大健康生态圈的新起点",
            "features": {
                "keywords": [
                    "药明康德",
                    "H股",
                    "挂牌上市",
                    "大健康生态圈"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "药明康德H股挂牌上市 构建大健康生态圈的新起点",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "肿瘤免疫疗法行业动态:依生生物免疫抗癌“孤儿药”获CDE受理临床申请",
            "features": {
                "keywords": [
                    "肿瘤免疫疗法",
                    "依生生物",
                    "孤儿药",
                    "CDE",
                    "临床申请"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "肿瘤免疫疗法行业动态:依生生物免疫抗癌“孤儿药”获CDE受理临床申请",
                "Correlation": 3,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]